Why the study?
Does pravastatin reduce recurrent coronary events in patients after myocardial infarction with average cholesterol levels and evidence of inflammation?
Does pravastatin reduce recurrent coronary events in patients after myocardial infarction with average cholesterol levels and evidence of inflammation?
Pravastatin may reduce recurrent coronary events after MI through nonlipid, anti-inflammatory effects.
Supports using statins for secondary prevention even with average cholesterol; extends the therapeutic rationale beyond.
Evidence of inflammation after MI is associated with increased risk of recurrent coronary events. Therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: